Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Going:
I appreciate it.
Take care,
Ann
Stock:
Thanks.
Ann
Nick:
I too believe that Richard's speaker/spokesman role may not be within his area of expertise. Hopefully, his management skills provide DNAP with the kinds of foundations for building and developing our company into multiple-levels of financial growth. I sense he is doing just that. - JMHO
Ann
Posted on RB:
Good exposure for DNAP
http://www.wallstreetreporter.com/linked.php?id=16659#Transcript
Ann
Stock:
World-wide EPO - interesting - sorry, too much laundry piled up - lol
http://www.dragonbiotech.com/archive.asp?id=33
Ann
HERE'S THE DNAP'S CONNECTION TO DNA PHENOMICS:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
DNAP Eye Witness Test:
http://transobj.workopolis.com/servlet/Content/fasttrack/20050625/DNA25?section=Biotech
Ann
Developing a Super EPO:
http://www.noblood.com/forum/showthread.php?p=5177&mode=threaded
Ann
Some info on Biofrontera Convertible Bond:
http://www.biofrontera.com/IR/wsv.html
Ann
Altar:
OT:
"Good luck to all of us and I'll check our close in the morning."
Good luck, since on the morrow is Sat. - lol
Ann
Altar:
OT:
"...I meant my portfolio will be holier."
A Freudian slip? - lol - Cheers!
(w/green beer, that is)
Ann
Altar:
OT:
"an altar boy always appreciates a good red wine"
You must be very Holy! - lol
Happy St. Paddy's
Ann
Going Up:
I agree
And a Happy St. Patrick's Day to all...May the Bluebird of Happiness...(well you might know the rest - lol)
Ann
Illumina, Inc.
http://www.illumina.com/
Ann
DNAPrint All Recent News
http://news.moneycentral.msn.com/ticker/rcnews.asp?Symbol=US%3ADNAG
Ann
Willy!
Ann
Wrl & Non:
Hope we continue to keep up that upward trend...
Have a great one!
Ann
A different source, 3/15/06, for DNAP/EPO info:
http://www.pharmaceutical-business-review.com/article_news.asp?guid=49B75143-9903-42E4-918A-DF45852D...
Ann
Geob:
OT:
Thanks for clearling it up and for the hope of good news!
Take care,
Ann
Geob:
OT:
"but I live in Canada"
You told me once via your post here that you lived in Huntington Beach, CA and all this time I thought we were neighbors. What happened to that? Not that it matters, just curious...w/no explanation required.
Can't wait to find out what you know, if in fact you really know what you're all a buzz about.
Take care,
Ann
Virgil:
I had posted it some time ago. But, good find on your part.
Take care,
Ann
Cosmic:
Very impressive!
Have a great day,
Ann
Hey Geob:
I've been here since day 1 and definitely a long!
Thanks - and a nice day to you,
Ann
Here's the link:
DNAPrint enters neurotherapeutics collaboration
Published: 06 Mar 2006
Related Research
DNAPrint enters neurotherapeutics collaboration
DNAPrint Genomics has revealed that it is to collaborate with the Massachusetts College of Pharmacy and Health Sciences on the potential development of Ritalin-like compounds as possible medications for drug abuse, ADHD and depression.
The compounds are analogs of Novartis' Ritalin, used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
The research will be conducted under the supervision of Dr Mark Froimowitz, a researcher at the Boston-based college, who recently licensed the compounds to DNAPrint Genomics.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," stated DNAPrint chief medical officer Dr Hector Gomez. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
Ann
DNAP enterq Neurothoropuetics collaboration:
http://sidesearch.lycos.com/?query=dnaprint&first=1&hurl=http%3A%2F%2Fwww%2Eancestrybydna%2E...
Ann
Lest You Forget: Excerps from Tony's 1st Newsletter to Investors:
"When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.
We have assembled a world-class laboratory with state-of-the-art equipment. We are sequencing well over 1 Million bases per week and scoring about 2,000 genotypes per day.
We have assembled what may well be the most extensive, detailed and valuable pharmacogenomics specimen databank in the world. We have had the foresight to collect multi-drug consent from our donors, and to log everything in their patient files into our database. No other company does this. Since most of our patients are on multiple medications and since we genotype every person at every pharmaco-relevant marker (unlike our competition), we have the ability to perform multiple and simultaneous pharmacogenomics projects. Please appreciate what this means. Using this type of “master” databank, DNAPrint will be able to outrun its competition in getting pharmacogenomics products discovered and developed to market."
Ann
From the Forensic Institute Series 2006 - DNA Witness now distributed by Reliagene & "ORCHID":
"Focusing in on specific facial characteristics, we offer our Retinome™ service for the determination of iris color solely from the DNA. Cases where skeletal remains of a victim need more definitive information for facial reconstruction can now place the most likely eye color in the clay model or sketch. With RetinomeÔ and DNAWitnessÔ combined, forensic artists will have more powerful tools than ever before.
Cold case files, suspect-less cases are a perfect opportunity to use DNAWitness™. A sample can be provided directly to DNAPrint genomics, Inc. or to one of our authorized distributors, ReliaGene Technologies, Inc., and Orchid Biosciences, Inc.
Ann
Dorsey:
Nite to you also - hopefully, all the "good stuff" will happen to us in our lifetime - lol
Ann
DNAP's Family Tree Legends now 5.0 - take a tour:
http://www.familytreelegends.com/software/whatsnew
Ann
"DNAPrint's first test/drug combination is PT-401, being developed in collaboration with Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC). PT-401 is a more powerful version of erythropoietin used for the treatment of anemia in renal dialysis patients (end stage renal disease). This "Super EPO" dimer protein drug is currently in pre-clinical development and will be targeted to patients with a genetic disposition indicating their propensity to have the best clinical response.
DNAPrint is also collaborating with the H. Lee Moffitt Cancer Center on the development of two other pharmacogenomic products: OVANOME™, a test for predicting an ovarian cancer patient's response to TAXOL/Carboplatin treatment, and STATINOME™, a test for predicting adverse response to cholesterol lowering medicines known as Statins.
Ann
Formation of DNAP Pharmaceuticals:
"We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products."
Data Monitor and the Pharmaceutical Manufacturer's Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year, driven primarily by a flood of new drug targets and the increase in the U.S. demand for drug treatments as the baby boomer population ages. Many of these targets were identified through genomics, opening the way for DNAPrint genomics to develop theranostic drugs to reduce side effects and provide greater efficacy through accompanying genomic response tests designed to ensure that patients receive the appropriate medication and dosage."
Ann
Dorsey:
Thanks. I don't recall seeing the version either. That's why I posted it.
My best to you,
Ann
Of course (in article) there are also the skeptics.
Ann
Though 8/05 - USA Today article gives DNAP great credit:
http://www.usatoday.com/news/nation/2005-08-16-dna_x.htm
Ann
Mass. College of Health Sciences:
http://www.mcphs.edu/
Ann
DNAP CRIME SCENE SOLUTIONS:
http://www.genetree.com/product/dna-detective.asp
Ann
DNAG removed from SHO?
http://www.stockhouse.com/news/news.asp?tick=IESR&newsid=3064196
Ann
World News,stocks to watch:
http://cgi.wn.com/?template=worldnews%2Fsearch.txt&action=search&...t=0&SearchString=dna...
Ann
Altar:
Don't forget Jever000 (three digits) is the latest. I believe this is an alias. (I wonder where Geob is?) I didn't say it - lol Altar: Jever00 original poster.
Take care,
Ann